178 related articles for article (PubMed ID: 29931401)
21. Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer.
Cohen SJ; Leichman CG; Yeslow G; Beard M; Proefrock A; Roedig B; Damle B; Letrent SP; DeCillis AP; Meropol NJ
Clin Cancer Res; 2002 Jul; 8(7):2116-22. PubMed ID: 12114411
[TBL] [Abstract][Full Text] [Related]
22. The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors.
Peters GJ; Noordhuis P; Van Groeningen CJ; Giaccone G; Holwerda U; Voorn D; Schrijvers A; Schornagel JH; Beijnen JH; Fumoleau P; Schellens JH
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4072-6. PubMed ID: 15217941
[TBL] [Abstract][Full Text] [Related]
23. Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 may be effective against peritoneal dissemination in gastric cancer.
Yamagata S; Nakata B; Hirakawa K
Oncol Rep; 2004 Nov; 12(5):973-8. PubMed ID: 15492780
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic evaluation of novel oral fluorouracil antitumor drug S-1 in Chinese cancer patients.
Zhuang ZX; Zhu H; Wang J; Zhu MG; Wang H; Pu WY; Bian HH; Chen L; Zhang H
Acta Pharmacol Sin; 2013 Apr; 34(4):570-80. PubMed ID: 23396375
[TBL] [Abstract][Full Text] [Related]
25. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
Fukushima M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients.
Comets E; Ikeda K; Hoff P; Fumoleau P; Wanders J; Tanigawara Y
J Pharmacokinet Pharmacodyn; 2003 Aug; 30(4):257-83. PubMed ID: 14650374
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function.
Ikeda M; Furukawa H; Imamura H; Shimizu J; Ishida H; Masutani S; Tatsuta M; Kawasaki T; Satomi T
Cancer Chemother Pharmacol; 2002 Jul; 50(1):25-32. PubMed ID: 12111108
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic and bioequivalence study between two formulations of S-1 in Korean gastric cancer patients.
Lee HW; Seong SJ; Kang WY; Ohk B; Gwon MR; Kim BK; Cho S; Cho K; Sung YK; Yoon YR; Kim JG
Drug Des Devel Ther; 2019; 13():3127-3136. PubMed ID: 31564829
[TBL] [Abstract][Full Text] [Related]
29. Effect of Sipjeondaebo-Tang on the Pharmacokinetics of S-1, an Anticancer Agent, in Rats Evaluated by Population Pharmacokinetic Modeling.
Kim TH; Shin S; Shin JC; Bulitta JB; Weon KY; Yoo SD; Park GY; Jeong SW; Kwon DR; Min BS; Woo MH; Shin BS
Molecules; 2017 Sep; 22(9):. PubMed ID: 28880240
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis.
Tominaga K; Higuchi K; Okazaki H; Suto R; Hamaguchi M; Tanigawa T; Sasaki E; Shiba M; Watanabe T; Fujiwara Y; Oshitani N; Matsumoto T; Arakawa T
Oncology; 2004; 66(5):358-64. PubMed ID: 15331922
[TBL] [Abstract][Full Text] [Related]
31. [New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
Shirasaka T; Tsukuda M; Inuyama Y; Taguchi T
Gan To Kagaku Ryoho; 2001 Jun; 28(6):855-64. PubMed ID: 11432358
[TBL] [Abstract][Full Text] [Related]
32. [Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil].
Yamada Y
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():37-41. PubMed ID: 16897970
[TBL] [Abstract][Full Text] [Related]
33. Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors.
Scheulen ME; Saito K; Hilger RA; Mende B; Zergebel C; Strumberg D
Cancer Chemother Pharmacol; 2012 Mar; 69(3):753-61. PubMed ID: 22020317
[TBL] [Abstract][Full Text] [Related]
34. Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin.
Peer CJ; McManus TJ; Hurwitz HI; Petros WP
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Jun; 898():32-7. PubMed ID: 22565063
[TBL] [Abstract][Full Text] [Related]
35. Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats.
Yoshisue K; Hironaga K; Yamaguchi S; Yamamoto A; Nagayama S; Kawaguchi Y
Cancer Chemother Pharmacol; 2000; 46(1):51-6. PubMed ID: 10912578
[TBL] [Abstract][Full Text] [Related]
36. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Shirasaka T; Shimamoto Y; Kato T; Fukushima M
Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
[TBL] [Abstract][Full Text] [Related]
37. Alternate-day oral therapy with TS-1 for advanced gastric cancer.
Arai W; Hosoya Y; Hyodo M; Yokoyama T; Hirashima Y; Yasuda Y; Nagai H; Shirasaka T
Int J Clin Oncol; 2004 Jun; 9(3):143-8. PubMed ID: 15221596
[TBL] [Abstract][Full Text] [Related]
38. [Pharmacokinetics of 5-FU after S-1 oral administration for adjuvant chemotherapy in gastric cancer patients].
Matsumoto H; Hirai T; Hirabayashi Y; Murakami H; Higashida M; Kawabe Y; Fuchimoto M; Fujikura H; Hato S; Urakami A; Yamashita K; Tsunoda T
Gan To Kagaku Ryoho; 2007 Jun; 34(6):869-73. PubMed ID: 17565248
[TBL] [Abstract][Full Text] [Related]
39. Alternative pharmacokinetics of S-1 components, 5-fluorouracil, dihydrofluorouracil and alpha-fluoro-beta-alanine after oral administration of S-1 following total gastrectomy.
Kim WY; Nakata B; Hirakawa K
Cancer Sci; 2007 Oct; 98(10):1604-8. PubMed ID: 17683513
[TBL] [Abstract][Full Text] [Related]
40. Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients.
Kochi M; Fujii M; Kanamori N; Kaiga T; Aizaki K; Takahashi T; Takayama T
Cancer Chemother Pharmacol; 2007 Oct; 60(5):693-701. PubMed ID: 17690883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]